Free Trial
NASDAQ:PCRX

Pacira BioSciences (PCRX) Stock Price, News & Analysis

Pacira BioSciences logo
$22.35 -0.71 (-3.06%)
Closing price 03:59 PM Eastern
Extended Trading
$22.36 +0.01 (+0.03%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pacira BioSciences Stock (NASDAQ:PCRX)

Advanced

Key Stats

Today's Range
$22.32
$23.06
50-Day Range
$22.07
$27.22
52-Week Range
$15.50
$27.64
Volume
264,485 shs
Average Volume
762,123 shs
Market Capitalization
$1.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.40
Consensus Rating
Hold

Company Overview

Pacira BioSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

PCRX MarketRank™: 

Pacira BioSciences scored higher than 75% of companies evaluated by MarketBeat, and ranked 257th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Pacira BioSciences has a consensus price target of $33.40, representing about 49.3% upside from its current price of $22.37.

  • Amount of Analyst Coverage

    Pacira BioSciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about Pacira BioSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Pacira BioSciences are expected to grow by 6.64% in the coming year, from $2.41 to $2.57 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pacira BioSciences is -8.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pacira BioSciences is -8.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pacira BioSciences has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Pacira BioSciences' valuation and earnings.
  • Percentage of Shares Shorted

    15.31% of the float of Pacira BioSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Pacira BioSciences has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Pacira BioSciences has recently increased by 1.21%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Pacira BioSciences does not currently pay a dividend.

  • Dividend Growth

    Pacira BioSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.31% of the float of Pacira BioSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Pacira BioSciences has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Pacira BioSciences has recently increased by 1.21%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Pacira BioSciences has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Pacira BioSciences this week, compared to 8 articles on an average week.
  • Search Interest

    2 people have searched for PCRX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $116,267.00 in company stock.

  • Percentage Held by Insiders

    Only 6.40% of the stock of Pacira BioSciences is held by insiders.

  • Percentage Held by Institutions

    99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pacira BioSciences' insider trading history.
Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PCRX Stock News Headlines

GOLD ALERT
Gold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" Eifrig says history shows it could be on the verge of its biggest bull run in over half a century.tc pixel
See More Headlines

PCRX Stock Analysis - Frequently Asked Questions

Pacira BioSciences' stock was trading at $18.84 at the start of the year. Since then, PCRX stock has increased by 18.7% and is now trading at $22.3650.

Pacira BioSciences, Inc. (NASDAQ:PCRX) released its quarterly earnings results on Tuesday, August, 5th. The company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.01. The firm's revenue for the quarter was up 1.7% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional shareholders of Pacira BioSciences include Assenagon Asset Management S.A. (0.52%), Voya Investment Management LLC (0.04%), Toth Financial Advisory Corp (0.03%) and GAMMA Investing LLC (0.01%). Insiders that own company stock include David M Stack, Daryl Gaugler, Frank D Lee, Kristen Williams, Jonathan Slonin, Lauren Riker, Roy Winston, Charles A Reinhart III, Kristen Marie Williams, Lauren Bullaro Riker, Anthony Molloy, Mark A Kronenfeld, Mark Froimson and Marcelo Bigal.
View institutional ownership trends
.

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
8/05/2025
Today
10/10/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PCRX
CIK
1396814
Employees
720
Year Founded
2006

Price Target and Rating

High Price Target
$65.00
Low Price Target
$18.00
Potential Upside/Downside
+48.6%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
9.33
P/E Growth
N/A
Net Income
-$99.56 million
Net Margins
-18.08%
Pretax Margin
-15.11%
Return on Equity
13.29%
Return on Assets
6.61%

Debt

Debt-to-Equity Ratio
0.50
Current Ratio
2.38
Quick Ratio
1.91

Sales & Book Value

Annual Sales
$705.85 million
Price / Sales
1.43
Cash Flow
$4.15 per share
Price / Cash Flow
5.42
Book Value
$16.86 per share
Price / Book
1.33

Miscellaneous

Outstanding Shares
44,933,000
Free Float
42,057,000
Market Cap
$1.01 billion
Optionable
Optionable
Beta
0.40

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:PCRX) was last updated on 10/10/2025 by MarketBeat.com Staff
From Our Partners